TR-1: Notification of major holdings

About this update from Thalia Therapeutics Plc

TR-1: S tandard form for notification of major holdings     1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : N4 Pharma PLC 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights An acquisition or disposal of financial instruments An event changing the breakdown of voting rights x Other (please specify) iii : 3. Details of person subject to the notification obligation iv Name MATHENZ MARC KAY City and country of registered office (if applicable) 4. Full name of shareholder(s) (if different from 3.) v Name   City and country of registered office (if applicable)   5. Date on which the threshold was crossed or reached vi : 23 April 2025 6. Date on which issuer notified (DD/MM/YYYY): 23 May 2025 7. Total positions of person(s) subject to the notification obligation   % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuer vii Resulting situation on the date on which threshold was crossed or reached 8.89% 8.89% 832,280,349 Position of previous notification (if applicable) 9.12%   9.12%     8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rights ix % of voting rights Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) GB00BYW8QM32 74,000,000 8.89% SUBTOTAL 8. A 74,000,000 8.89%       B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights       SUBTOTAL 8. B 1           B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Physical or cash settlement xii Number of voting rights % of voting rights         SUBTOTAL 8.B.2           9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii X Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary) Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold           10. In case of proxy voting, please identify: Name of the proxy holder UOB KAYHIAN SINGAPORE PTE LTD The number and % of voting rights held 74,000,000 (8.89%) The date until which the voting rights will be held NA   11. Additional information xvi       Place of completion SINGAPORE Date of completion 23 May 2025  

View stock analysis, news, and events for Thalia Therapeutics Plc